Hologic (HOLX) late Wednesday reported fiscal Q1 non-GAAP earnings of $1.03 per diluted share, up from $0.98 a year earlier.
Analysts polled by FactSet, on average, expected $1.02.
Net sales for the quarter ended Dec. 28 were $1.02 billion compared with $1.01 billion a year earlier. Analysts expected $1.02 billion.
For Q2, the health care company is looking for non-GAAP EPS of $1.00 to $1.03 on revenue of $995 million to $1.01 billion. Analysts are expecting $1.04 and $1.03 billion, respectively.
For 2025, Hologic is now projecting non-GAAP EPS of $4.25 to $4.35 compared with the analyst consensus expecting $4.26.
It cut projected revenue for 2025 to $4.05 billion to $4.1 billion from its prior range expecting $4.15 billion to $4.2 billion. The analyst consensus is expecting $4.16 billion.
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。